In December 2020, the US Food and Drug Administration (FDA) granted emergency use authorization (EUA) to both the Pfizer-BioNTech and Moderna coronavirus disease 2019 (COVID-19) vaccines. Since then, ISMP has received numerous voluntary reports of COVID-19 vaccine errors or hazards through the ISMP National Vaccine Errors Reporting Program (VERP), the ISMP National Consumer Medication Errors Reporting Program (C-MERP), and via email correspondence from professional colleagues.
In this podcast, we discuss which COVID-19 vaccines currently available and the recommended dosing and booster schedule for each. We review some of the errors ISMP has received, including those related to staff shortages, labeling and packaging of vaccines, as well as preparing and administering the vaccines. The discussion also includes recommendations from ISMP to prevent these types of errors and patient harm.
Speakers:
Alex Savchuk, PharmD, Post-Doctoral Fellow, Novartis, Name Creation & Regulatory Strategy
Sadik Owolewa, PharmD, 2022-2023 FDA/ISMP Fellow, Institute for Safe Medication Practices
This podcast is supported by Novartis, Name Creation & Regulatory Strategy.
